The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis

BMC Cancer

Table 2 Stratified analysis of pooled hazard ratios of lactate dehydrogenase on overall survival

			Pooled HR (95 % CI)			Heterogeneity
Stratified analysis	No. of studies	No. of patients	Fixed	Random	Meta-regression on p-value	I² (%)	p-value
Study location					0.581
Asia	4	580	1.66 [1.29, 2.14]	1.82 [1.14, 2.9]		67.9	0.025
Europe	19	5276	1.66 [1.53, 1.80]	1.67 [1.40, 2.0]		69.5	<0.001
Other regions	5	1065	1.85 [1.52, 2.25]	2.07 [1.45, 2.94]		64.1	0.025
Age					0.563
≤ 50	2	191	1.98 [1.33, 2.94]	2.31 [1.04, 5.13]		63.1	0.1
No limitation	22	5623	1.70 [1.57, 1.84]	1.77 [1.51, 2.08]		68.5	<0.001
Number of patients					0.68
≥ 100	22	6428	1.68 [1.56, 1.81]	1.73 [1.49, 2.01]		69	<0.001
< 100	6	439	1.84 [1.66, 2.04]	1.96 [1.11, 3.43]		60.3	0.28
Metastasis					0.059
Yes	16	5044	1.84 [1.66, 2.04]	1.96 [1.61, 2.37]		64.4	<0.001
No	5	883	1.53 [1.29, 1.82]	1.21 [0.79, 1.86]		74.4	0.028
LDH cutoff					0.309
> 300 U/L	7	764	1.93 [1.50, 2.49]	1.98 [1.41, 2.77]		29.1	0.206
250–300 U/L	5	1028	1.61 [1.38, 1.88]	1.84 [1.08, 3.13]		88.6	<0.001
< 250 U/L	6	1174	1.58 [1.31, 1.90]	1.44 [0.94, 2.21]		75.4	0.001
Chemotherapy with anti-angiogenesis drugs					0.64
Yes	5	1675	1.75 [1.51, 2.02]	1.78 [1.41, 2.23]		57.3	0.053
No	16	4166	1.60 [1.46, 1.75]	1.65 [1.40, 1.94]		54.8	0.003
Study type					0.863
non-RCT^a	22	3683	1.66 [1.51, 2.02]	2.03 [1.31, 3.13]		71.5	<0.001
RCT	5	3238	1.73 [1.54, 1.94]	1.73 [1.54, 1.94]		<0.01	0.535
Risk of bias					0.31
High	16	3142	1.52 [1.36, 1.68]	1.63 [1.28, 2.09]		76.5	<0.001
Low	11	3799	1.87 [1.69, 2.07]	1.65 [1.28, 2.12]		<0.01	0.655

ISSN: 1471-2407